PressMarch 27, 2025 Numinus Approved as a State-Certified Natural Medicine Training Program in Colorado
PressMarch 20, 2025 Neural Therapeutics Commences Trading, Provides Update on Growth Initiatives and Engages Investor Relations Consultants
PressMarch 20, 2025 Filament Health Announces Positive Data From Phase 2 Study of PEX010 in Patients With Alcohol Use Disorder
PressMarch 20, 2025 Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
PressMarch 20, 2025 atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
PressMarch 20, 2025 Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
PressMarch 11, 2025 Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
PressMarch 11, 2025 MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
PressMarch 11, 2025 Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
PressMarch 11, 2025 Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
PressMarch 11, 2025 PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
PressMarch 11, 2025 Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
PressMarch 11, 2025 Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order
PressMarch 8, 2025 atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
PressFebruary 14, 2025 Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
